Merck's Lipfendra becomes first oral PCSK9 inhibitor approved by FDA
The US Food and Drug Administration has approved Lipfendra (enlicitide), a once-daily pill that cuts LDL cholesterol by up to 59%, ending a decades-long era in which this class of drug was available only by injection.